D-0890-2018 Class II Terminated
FDA drug recall D-0890-2018 was initiated by Ingenus Pharmaceuticals Llc on Jun 8, 2018 and is designated Class II. Reason for recall: Superpotent Drug: High out of specification assay value results for potency. The recall status is terminated (terminated May 1, 2019). Affected quantity: 34964 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 11, 2018
- Initiation Date
- Jun 8, 2018
- Termination Date
- May 1, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 34964 vials
Product description
Irinotecan Hydrochloride Injection, USP, 100 mg/5 mL (20 mg/mL), 1 x 5 mL Single Dose Vial, Rx Only, Manufactured for: Ingenius Pharmaceuticals, LLC, Orlando, FL 32839-6408; Manufactured by: Ingenius Pharmaceuticals, GmbH Ticino 6917, Switzerland, NDC 50742-402-05.
Reason for recall
Superpotent Drug: High out of specification assay value results for potency.
Distribution pattern
Nationwide in the USA
Code information
Lot #: 17034-1, 17035-1, 17036-1; Exp. 08/19
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0890-2018
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026